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Preliminary Studies on the Toxicity and
Metabolism of Palladium and Platinum
by W. Moore,* D. Hysell,* L.Hall,* K. Campbell,* and J. Stara*
Preliminary data are given on the LDw of PdCI2 following different routes of exposure
and on the LDw of PtCL following intravenous exposure.
The retention, tissue distribution, and excretion of 103Pd and "1Pt in rats was deter-
mined following oral, intravenous, intratracheal, and inhalation exposure. The. highest
retention for both 1"'Pd and "'Pt was obtained following intravenous dosing, and the
lowest retention occurred after oral dosing. Following a single oral dose, almost all of the
"'Pd and "'Pt was excreted in the feces due to nonabsorption, whereas after intravenous
dosing, similar quantities were excreted in both the urine and feces. Tissues containing
the highest concentrations of these metals were the kidney, spleen and liver. Following
intravenous dosing of pregnant rats, a small amount of "..Pd and ""Pt was found in the
fetuses.
Introduction
Automotive manufacturers have indicated
that palladium (Pd) will be used in connec-
tion with platinum (Pt) in automotive cata-
lytic converters. These converters are de-
signed to reduce the concentrations of carbon
monoxide (CO) and hydrocarbons (HC) in
the exhaust stream by oxidizing them into
carbon dioxide and water. The control of
the concentrations of CO and HC in auto-
motive emissions is necessary for light-duty
vehicles to comply with the CO and HC emis-
sion standards set forth in the Clean Air
Amendments of 1970 (1). With the use of
Pd and Pt in automotive catalytic converters,
there is the possibility that some of the ma-
terial will be emitted to the atmosphere or
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enter into other segments of the environment
following degradation or disposal of worn-
out converters.
At the present time, the authors are not
aware of any information concerning the
chemical form of Pd or Pt which may be
emitted in the exhaust. It can be speculated
that the attrition products from the catalyst
could include: particulate composed of the
metals combined with substrate material;
Pd and Pt oxides; Pd and Pt metals; possibly
other chemical forms.
Although toxicological data on these two
metals is extremely limited, reports indicate
that toxicity varies with the chemical form
(2-9). In the studies that are discussed
today, we have used the soluble salts of Pd
and Pt in order to ascertain some of the
basic toxicological and metabolic aspects. It
is realized that the availability and metab-
olism of other chemical forms or substrate
material containing Pd and Pt may be dif-
ferent; however, these data should serve as
April 1975 63a guideline for additional studies on the bio-
logical effects of these two elements.
Methods
The outbred albino rats (Charles River
CD-1-strain) used in these studies were
maintained on a commercial diet (Purina
Lab. Chow) and tapwater ad libitum except
where otherwise noted. Rabbits were ob-
tained from a local supplier and fed a com-
mercial diet (Purina Rabbit Chow) and
tapwater ad libitum.
Toxicity Studies of Pd and Pt
Animals were given PdCl2 or PtCl4 by
the following routes: orally (PO), intra-
venously (IV), intraperitoneally (IP); and
intratracheally (ITR). All solutions were
prepared in saline with no pH adjustment.
Four groups (10 animals/group) of rats
were given Pd or Pt in the drinking water
(pH 3.0), and appearance, body weight, and
water consumption were noted. The concen-
trations used were 92 and 184 ppm K2PdC14
and 235 and 470 ppm K2PtCl4. Water for
control animals also had a pH 3.0.
Metabolism Studies of Pd and Pt
The various treatment groups consisted of
those (rats) who received Pd or Pt by the
following routes: ITR, PO, IV, or by inhala-
tion.
Intratracheal Administration: Ten fasted
male rats weighing 180-200 g, were anesthe-
tized and the trachea isolated through a ven-
tral midline incision. 103PdC12 (25 /ACi in 0.1
ml saline) was injected and the incision
closed. Rats were counted for whole body
retention of 103Pd.
Oral Administration: Twenty fasted
male rats, 180-200 g, were lightly anesthe-
tized with ether and given 25 MACi of 103PdC12
in 0.2 ml saline by stomach tube. Ten rats
were placed in metabolism cages for collec-
tion of 24-hr urine and fecal samples to de-
termine routes of excretion and for determi-
nation of whole-body retention of 103Pd. The
other 10 rats were sacrificed 24 hr following
dosage to establish organ distribution of the
103Pd. Fifteen nonfasted suckling rats, 30 g,
were given a single dose of '03PdC12 (25MfCi
in 0.2 ml saline) by stomach tube. These
animals were maintained for comparison
with retention of T03Pd in the adult rats.
Intravenous Administration: Twenty
male rats, 180-200 g, were given 25 ,uCi
PdCl2 in 0.1 ml saline IV in a tail vein. Ten
rats were sacrificed 24 hr later for organ dis-
tribution; 10 rats were placed in metabolism
cages for collection of 24-hr samples of urine
and feces and for whole body counting to
determine retention. Thirteen female rats
(16 days pregnant) were given 25 uCi
103PdCl2 IV and maintained in metabolism
cages for collection of feces and urine. They
were sacrificed 24 hr after dosage for deter-
mination of organ distribution and placental
transfer of the 103Pd.
Inhalation Administration: The animal
exposure system consisted of a multiple-
animal exposure chamber (88 rats) supplied
with aqueous aerosol from a nebulizer; the
aerosol droplets passed through a drying
cylinder to produce the dry solid particles
needed for the inhalation exposure.
The exposure to a platinum particulate in-
volved a 5.8 ml supply of the nuclide 191'193Pt,
assaying 7 mCi in the form of 191Pt+4 in 1M
HCI; it was mixed with stable PtCl4 in
aqueous solution to give a final 10 ml volume
of approximately 2.2 mg/ml. On the basis
of such a concentration value and of a me-
dian droplet diameter of 6-8 MLm generated
by the nebulizer, it was calculated that a dry
particle of PtCl4 with an aerodynamic size
diameter of nearly 1.0 Mim would be obtained.
The particulate load was measured at 5.0
mg/m3 over the 48-min exposure period.
The exposure to palladium particulate
made use of a 4 ml supply of the nuclide '103Pd,
assaying 5 mCi in the PdCl2 form in 0.6M
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stable PdCl2 in a similarly HCl-acidified solu-
tion to give a final 10 ml volume of approxi-
mately 2.3 mg/ml. A 1.0 /Am aerodynamic
diameter was intended. Since the radioactive-
stable mix solution was aerosolized in just
30 min, the atmospheric concentration pro-
duced was measured as 7.2 mg/M3.
Sacrifice and Tissue Sampling
All rats were euthanatized with an over-
dose of chloroform anesthesia. Samples col-
lected routinely were blood, heart, lung, liver,
kidney, adrenal gland, pancreas, abdominal
fat, spleen, skeletal muscle, bone, brain, tes-
ticle, and ovary. In the pregnant females,
four placentas, and four fetuses were taken
from each pregnant rat, and a pooled sample
of fetal livers was also saved.
Radioactive Determinations
103Pd in 0.6M HCI was diluted as indicated
and used in all the studies. The isotope has
a half-life of 17 days and a 0.362 MeV y. Im-
mediately after dosing, whole-body counts
were made on all animals used in the reten-
tion studies. The animals were counted daily
for the first few days, and then every other
day for the duration of the experiment. A
200-channel y spectrometer with a 5-in. NaI
(TI) crystal was used for whole-body counts.
Tissue, urine, and feces samples were
counted in a well-type, refrigerated scintilla-
tion spectrometer.
191"'93Pt in 0.5M HCI was diluted and used
as described in the Pd studies.
The solution contained at least 50% 191Pt,
and only the 19'Pt y was counted. All values
were corrected for decay (191Pt has a half-
life of 3 days).
Results
Palladium Toxicity
By using the method of Deichman and
LeBlanc (10), the approximate LD50 of PdCl2
Table 1. Acute lethal toxicity of PdCI2.
Species Approx. LD5o, mg/kg Route
Rat 5 IV
Rat 70 IP
Rat 200 PO
Rat 6 ITR
Rabbit 5 IV
was determined for IV, IP, ITR, and PO
routes of administration. The results are
shown in Table 1. Marked differences were
noted among the different routes of adminis-
tration, ranging from 5 mg/kg for IV to
greater than 200 mg/kg for PO.
Using the more precise method of Litch-
field and Wilcoxon (11), the IV and IP LD,0
(14 days) were determined. The LD5,0 (14
days) was calculated to be 3.0 mg PdCl2/kg
with 95% confidence limits of 2.57-3.49. The
slope was found to be 1.43 with a 95% con-
fidence limit of 1.15-1.77. The x2 test indi-
cated that the data were not significantly
heterogenous. Following IP administration,
the LD5,, was calculated to be 123.0 (91.1-
166.1) mg PdCl2/kg with a slope of 1.84
(1.04-3.27); no significant heterogenicity
was noted.
Following acutely toxic IV doses of PdCl2,
death occurred very rapidly, with a sharp
threshold such that if exitus did not occur
within 5-10 min, the animals (both rats and
rabbits) survived the 14-day experimental
period. Clonic and tonic convulsions were
noted in rats and rabbits. Following IP in-
jection, necropsy findings indicated a chem-
ical type "burn" of the viscera in animals
dying within 24 hr. Gross pathologic exami-
nation of IP dosed survivors at 14 days
showed prominent peritonitis with numerous
visceral adhesions.
A limited number of rats from the intra-
venous and intraperitoneal studies were
housed in metabolism cages and several toxi-
cometric parameters were measured during
the 14-day observation period. Survivors of
an acutely toxic IV dose of PdCl2 exhibited
a 25%o decrease in water intake and urine
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Compound LDr0, mg/kg Slope LD5,,.
(95% confidence) (95% confidence) gM/kg
PdCl2 3.0 (2.6-3.50) 1.43 (1.1 -1.8) 16.9
K2PdCl4 6.4 (6.0-6.8) 1.14 (0.83-1.2) 19.6
(NH4)2PdCI4 5.6 (4.9-6.4) 1.31 (0.96-1.8) 19.7
excretion. Following intraperitoneal dosing,
a 7% reduction in body weight was observed
with up to 80%o reduction in food intake.
Water intake was markedly reduced initially
and then returned to control levels or above.
Proteinuria was noted in all animals follow-
ing both routes of administration. Elevated
urinary ketone bodies were observed in some
animals following both routes of dosing.
In order to ascertain the effect of chemical
form on toxicity, the LD50 of K2PdCl4 and
(NH3)2PdCl4 were determined (Table 2). The
LD5,, when expressed in micromoles of Pd
was very similar for the three chemical
forms.
In the two groups of rats maintained for
33 days on drinking water containing 92
ppm and 194 ppm K2PdCl4, respectively, there
were no abnormalities noted in general ap-
pearance, body weights or urinalysis.
Platinum Toxicity
The results of a preliminary range finding
study on the acute toxicity of IV PtCl4 in rats
is given in Table 3. The high incidence of
mortality at the lowest dose precluded deter-
mination of the LD50 (14 days).
However, the lowest dose would appear to
be a reasonable approximation.
In two groups of rats maintained for 23
days on drinking water containing 235 ppm
and 470 ppm K,PtCl4, respectively, there was
a decrease in weight gain and water consump-
tion. For the high dose level the weight gain
decreased 14.7%o and the water intake de-
creased 32.8%. No gross pathological changes
were found at necropsy. Additional studies
are currently in progress on Pt toxicity.
Table 3. Acute intravenous toxicity of PtCI4 in rats.
PtCl4 dose, No. of rats Cumulative Mortality,
mg/kg per group deaths %
41.4 10 10 100
36.7 10 9 90
31.4 10 9 90
26.2 10 4 40
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FIGURE 1. Whole body retention in adult rats of
103Pd following PO, IV, ITR administration and
whole body retention in suckling rats following
PO administration.
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Whole-Body Retention. Analysis of the
data for whole-body retention of 103Pd follow-
ing a single exposure disclosed that the route
of administration of the dose significantly
affected whole-body retention. The 103Pd re-
tained in rats, 1 to 28 days after dosing PO,
IV, or ITR is presented in Figure 1. Follow-
ing PO dosing, the retention curve declined
very rapidly during the first 3 days to about
0.4% of the initial dose. The initial rapid
clearance is attributed to passage of the un-
absorbed 103Pd through the gastrointestinal
tract. Extrapolation of the second compo-
nent of the retention curve to the intercept
indicated that absorption was less than 0.5%
of the initial dose. Retention of 103Pd by the
suckling rats following oral administration
was similar to the adults; however, the
amount absorbed and retained with time was
significantly higher.
The amount of 103Pd retained following
ITR dosing was significantly higher than for
PO dosing and also higher than inhalation
exposure (Fig. 2). The difference in reten-
tion between inhalation and ITR exposure
may be due in part, to protein binding of the
103Pd following injection. The greatest
amount of 103Pd retained over a period of
time occurred following IV administration.
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FIGURE 2. Whole-body retention of 1"Pd in adult
rats following ITR and inhalation exposure.
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FIGURE 3. Excretion of 1"Pd by adult rats following
PO and IV administration.
Excretion: Radioactive counts of 24-hr
urine and feces samples from the rats re-
ceiving the 103Pd PO showed that almost all
of the 103Pd was eliminated in the feces, and
only a trace amount was excreted in the
urine (Fig. 3). With IV administration,
103Pd was eliminated both in the urine and
feces in similar quantities. Toward the end
of the study, urinary excretion exceeded
fecal excretion.
Tissue Distribution: The distribution and
concentration of 103Pd was determined for
different tissues following PO and IV dosing.
Twenty-four hours after PO dosing, detect-
able quantities of 103Pd were found only in
the kidney and liver. The concentration in
the kidney was much greater than in the
liver. Twenty-four hours after IV dosing,
103Pd was found in all the tissues analyzed,
with the highest concentrations occurring in
April 1975 67the kidney, spleen, liver, adrenal gland, lung,
and bone, respectively.
The rats used in the whole-body retention
study were sacrificed 104 days after expo-
sure and the tissues counted. No significant
amounts of 103Pd were found in any of the
tissues from the group receiving the PO dose.
In the IV-dosed rats, the highest concentra-
tions of 103Pd were found in the spleen, kid-
ney, liver, lung, and bone. For the ITR-dosed
rats, the lung contained the most 103Pd fol-
lowed by kidney, spleen, bone, and liver.
Maternal/Fetal Uptake: Thirteen preg-
nant rats (16th day gestation) were each
given 25 uCi 103Pd IV and sacrificed 24 hr
later. During the 24-hr period, the pregnant
rats excreted 44.2% of the initial IV dose.
The amount excreted by the pregnant rats
was higher than the amount excreted by the
fasted adult male rats during the first 24-hr
period. The magnitude of the difference in
103Pd concentration among the maternal
organs and also between maternal tissues and
the fetuses is best shown by the counts per
gram of tissue, which are given in Table 4.
Table 4. 103Pd in maternal organs and fetuses.
Tissue Mean counts/g
Kidney 588,479
Liver 319,153
Ovary 29,625
Lung 29,21v
Bone 18,351
Blood 3,654
Placenta 58,321
Fetal liver 1,429
Fetus 757
The pattern of distribution and concen-
tration of 103Pd in maternal organs was simi-
lar to that previously found in the whole-
body IV experiment. Most of the fetuses
(35) contained a small amount of 0""Pd, and
the mean value for these fetuses is given in
Table 4. However, radioactive counts for 17
fetuses from five litters was not significantly
higher than background. The same pattern
of results was obtained for the fetal livers.
The amount of 103Pd found in the fetuses
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Percent of Initial
Ratained
Adult
IlV
Suckling Rat
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FIGURE 4. Whole body retention of "9'Pt in adult
rats following PO, IV, ITR administration. Also
given is the whole body retention in suckling rats
following PO administration.
indicated that Pd does not readily move
across the placental barrier in the rat.
Metabolism of Platinum
Whole-Body Retention: The whole-body
retention of 191Pt following a single exposure
was significantly affected by the route of
administration. The per cent of 19"Pt retained
in rats 1-28 days after dosing PO, ITR, and
IV is presented in Figure 4. Following oral
dosing, the total net gastrointestinal excre-
tion was extremely high, resulting in a rapid
decline of the retention curve to less than
1 o at the end of 3 days. The data indicated
that the rapid clearance was due to passage
of unabsorbed 19"Pt through the gastro-
intestinal tract. Extrapolation of the second
component of the retention curve to the inter-
cept indicated that less than 1%o of the initial
dose was absorbed.
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FIGURE 5. Whole body retention of "9lPt in adult
rats following ITR and inhalation exposure.
The whole-body retention of 191Pt follow-
ing ITR dosing was significantly higher than
for oral dosing. The excretion of approxi-
mately 50% of the initial dose during the
first 24 hr is attributed to mucociliary and
alveolar clearance. The retention of i9'Pt
following ITR administration was higher
than following inhalation exposure (Fig. 5).
Whole-body retention was the highest follow-
ing IV dosing; the short half-life precluded
an accurate determination of the biological
half-life.
Excretion: Radioactive counts of 24-hr
urine and feces samples from rats receiving
191Pt PO indicated that almost all of the 191Pt
was eliminated in the feces and only a small
amount was excreted in the urine (Fig. 6).
These values support the whole-body data
that showed that total net gastrointestinal
absorption was low. Following IV adminis-
tration, 191Pt was excreted in both the urine
and feces, but the urine contained a greater
quantity.
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FIGURE 6. Excretion of "'Pt in rats following PO
and IV administration.
Tissue Distribution: The distribution and
concentration of 191Pt in tissues was deter-
mined following PO and IV dosing. After a
single PO dose, the kidney and liver con-
tained the highest concentrations of 191Pt.
The -amount of radioactivity found in the
other organs was -not significantly higher
than background. Twenty-four hours after
IV dosing, i9'Pt was found in all the tissues
analyzed, although most tissues did not con-
tain concentrations of 191Pt which were
appreciably higher than that found in blood.
The large amount of 191Pt found in the kidney
suggests that this organ accumulates this
element. Concentrations higher than the
blood values were also found in the liver,
spleen, and adrenal gland. The lower count
for the brain suggested that 191Pt can be
April 1975 69Table 5. l9lPt in maternal organs and fetuses.
Tissue Mean courts/g
Kidney 127,064
Liver 43,375
Lung 1j,,981 Ovary 14,639
Blood 10,568
Bone 9,193
Brain 792
Placenta 27,750
Fetal liver 1,421
Fetus 432
transferred through the blood-brain barrier
only to a limited extent, possibly the circu-
lating 191Pt is complexed to lalge molecules
that do not cross the blood-brain barrier.
Maternal/Fetal Uptake: Fifteen preg-
nant rats (18th day gestation) were given
25 /LCi 191Pt IV and sacrificed 24 hr later.
During the 24-hr period, the pregnant rats
excreted 18.8% of the initial dose. The
amount excreted by the pregnant rats was
approximately the same as the amount
(19.3%) excreted by the adult male rats
during the first 24-hr period. The concen-
tration of 19'Pt per gram for different ma-
ternal tissues and fetuses is given in Table 5.
The data indicated that there was some
transplacental passage of 191Pt; however,
there appeared to be placental binding or
accumulation. 191Pt was present in all the
fetuses (60) counted.
Discussion
It has been stated that the use of catalytic
converters will involve exposing the general
population to low levels of Pt and Pd com-
pounds and that the exposure to Pt com-
pounds are likely to range from 1/100 to 1/10
of the threshold limit value for Pt salts (12).
The threshold limit value (TLV) for inhala-
tion of soluble Pt is 2 gg/m3. Data in the
literature suggest that the toxicity of Pt is
influenced by the chemical form; the chemical
forms of Pt and Pd associated with auto-
motive emissions and the chemical forms
that may exist in the environment have not
been adequately identified. The soluble salts
of Pd and Pt were selected for initial study
because of the paucity of information on the
toxicity and metabolism of these ions. In
future studies, the biological effects of the
metals, oxides of the metals and catalytic
attrition products containing Pd and Pt will
be investigated.
Although there would be some dermal
exposure, inhalation and ingestion would
probably comprise the majbr routes ofhuman
exposure to Pt and Pd. The results of these
studies indicate that Pt and Pd are not
readily absorbed followingingestion. The data
also indicate that absorption may be slightly
higher in the very young. Following inhala-
tion, somewhat more Pt and Pd were ab-
sorbed and retained in the animals. There
was some transplacental passage of Pt and
Pd but the significance to fetal development
is not known. It is obvious from these ob-
servations that additional information is
needed in order to determine the health
impact of these metals in the environment.
REFERENCES
1. Clean Air Act (42 U.S.C. 1857 et seq.) includes
the Clean Air Act of 1963 (P.L. 88-206), and
amendments made by the Motor Vehicle Air
Pollution Control Act, P.L. 89-272 (October 20,
1965), the Clean Air Act Amendments of 1966,
P.L. 89-675 (October 15, 1966), the Air Quality
Act of 1967, P.L. 90-148 (November 21, 1967),
and the Clean Air Amendments of 1970, P.L.
91-604 (December 31, 1970).
2. Christensen, G. M. Effects of metal cations and
other chemicals upon the in vitro activity of two
enzymes in the blood plasma of the white sucker,
Catostomus commersoni. Chem. Biol. Interac-
tions 4: 351 (1971-1972).
3. Hunter, D., Milton, R., and Perry, K. M. A.
Asthma caused by the complex salts of platinum.
Brit. J. Ind. Med. 2: 92 (1945).
4. Meek, F. F. Harrold, C. C., and McCord, C. P.
The physiological properties of palladium. Ind.
Med. Surg. 12: 447 (1943).
5. Orestano, G. The pharmacologic action of palla-
dium chloride. Bull. Soc. Ital. Biol. Sper. 8: 1154
(1933).
6. Parrot, J. L., et al. Platinum and platinosis.
Arch. Environ. Health 19: 685 (1969).
7. Roberts, A. E. Platinosis. Arch. Ind. Hyg. 4:
549 (1951).
70 Environmental Health Perspectives8. Saindelle, A., and Ruff, F. Histamine release by
sodium chloroplatinate. Brit. J. Pharmacol. 35:
313 (1969).
9. Schroeder, H. A., and Mitchener, M. Scandium,
chromium (VI), gallium, yttium, rhodium, palla-
dium, indium in mice: effects on growth and
life span. J. Nutr. 101: 1431 (1971).
10. Diechman, W. B., and LeBlanc, T. J. Determina-
tion of the approximate lethal dose with about
six animals. J. Ind. Hyg. Toxicol. 25: 415 (1943).
11. Litchfield, J. T., Jr., and Wilcoxon, F. J. A sim-
plified method of evaluating dose-effect experi-
ments. J. Pharm. Therap. 96: 99 (1949).
12. Greenfield, S. Internal EPA memo urges delay
in use of catalytic converter. Environ. Health
Letter 12(20): 1 (1973).
April 1975 71